Total Valuation
Sino Biopharmaceutical has a market cap or net worth of $13.27B. The enterprise value is $83.38K.
Market Cap$13.27B
Enterprise Value$83.38K
Share Statistics
Sino Biopharmaceutical has 18,682,953,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding18,682,953,000
Owned by Insiders15.79%
Owned by Institutions<0.01%
Financial Efficiency
Sino Biopharmaceutical’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 8.98%.
Return on Equity (ROE)0.08
Return on Assets (ROA)0.03
Return on Invested Capital (ROIC)8.98%
Return on Capital Employed (ROCE)0.14
Revenue Per Employee1.39M
Profits Per Employee304.03K
Employee Count22,838
Asset Turnover0.42
Inventory Turnover2.53
Valuation Ratios
The current PE Ratio of Sino Biopharmaceutical is 36.1. Sino Biopharmaceutical’s PEG ratio is -1.22.
PE Ratio36.1
PS Ratio3.15
PB Ratio3.27
Price to Fair Value3.27
Price to FCF13.21
Price to Operating Cash Flow14.13
PEG Ratio-1.22
Income Statement
In the last 12 months, Sino Biopharmaceutical had revenue of 31.83B and earned 2.34B in profits. Earnings per share was 0.13.
Revenue31.83B
Gross Profit26.13B
Operating Income6.95B
Pretax Income6.94B
Net Income2.34B
EBITDA7.26B
Earnings Per Share (EPS)0.13
Cash Flow
In the last 12 months, operating cash flow was 6.13B and capital expenditures -967.92M, giving a free cash flow of 5.16B billion.
Operating Cash Flow6.13B
Free Cash Flow5.16B
Free Cash Flow per Share0.28
Dividends & Yields
Sino Biopharmaceutical pays an annual dividend of $0.009, resulting in a dividend yield of 2.14%
Dividend Per Share$0.009
Dividend Yield2.14%
Payout Ratio78.06%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.23
52-Week Price Change-40.43%
50-Day Moving Average0.65
200-Day Moving Average0.72
Relative Strength Index (RSI)62.34
Average Volume (3m)1.20K
Important Dates
Sino Biopharmaceutical upcoming earnings date is Apr 1, 2027, TBA (Confirmed).
Last Earnings DateAug 19, 2026
Next Earnings DateApr 1, 2027
Ex-Dividend Date―
Financial Position
Sino Biopharmaceutical as a current ratio of 1.37, with Debt / Equity ratio of 52.72%
Current Ratio1.37
Quick Ratio1.28
Debt to Market Cap0.16
Net Debt to EBITDA1.20
Interest Coverage Ratio25.65
Taxes
In the past 12 months, Sino Biopharmaceutical has paid 1.63B in taxes.
Income Tax1.63B
Effective Tax Rate0.23
Enterprise Valuation
Sino Biopharmaceutical EV to EBITDA ratio is 15.01, with an EV/FCF ratio of 14.35.
EV to Sales3.42
EV to EBITDA15.01
EV to Free Cash Flow14.35
EV to Operating Cash Flow11.72
Balance Sheet
Sino Biopharmaceutical has $27.58B in cash and marketable securities with $17.17B in debt, giving a net cash position of $10.41B billion.
Cash & Marketable Securities$27.58B
Total Debt$17.17B
Net Cash$10.41B
Net Cash Per Share$0.56
Tangible Book Value Per Share$1.98
Margins
Gross margin is 82.43%, with operating margin of 21.84%, and net profit margin of 7.36%.
Gross Margin82.43%
Operating Margin21.84%
Pretax Margin21.81%
Net Profit Margin7.36%
EBITDA Margin22.79%
EBIT Margin19.76%
Analyst Forecast
The average price target for Sino Biopharmaceutical is $1.11, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$1.11
Price Target Upside56.89% Upside
Analyst ConsensusStrong Buy
Analyst Count14
Revenue Growth Forecast14.23%
EPS Growth Forecast-31.47%